Mission Bio’s Tapestri Single Cell Multi-Omics Platform for Exploratory Biomarker Analysis Supports Myeloproliferative Neoplasms (MPNs) Data Presentation at ASH 2025

Mission Bio’s Tapestri® Platform and custom assay development platform supported exploratory biomarker analysis for Incyte’s INCA033989 clinical trial for myeloproliferative neoplasms (MPNs), enabling single-cell DNA and protein profiling to better understand clonal evolution, treatment response, and resistance mechanisms.

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mission Bio, Inc., a leader in single-cell multi-omic solutions for precision medicine, announced that its Tapestri Platform and custom assay development supported initial exploratory biomarker analysis data presented by Incyte at the ASH 2025 conference in Orlando, Florida, in December. The data demonstrate Tapestri® Platform’s ability to accelerate the understanding of Myeloproliferative Neoplasms (MPNs) disease biology at the single-cell level.

Myeloproliferative neoplasms (MPNs) are a type of blood cancer caused by genetic mutations in blood-forming stem cells. These mutations—found in the JAK2, TPO-R, or CALR genes—lead to uncontrolled growth of certain blood cells. INCA033989, an investigational monoclonal antibody, targets mutant calreticulin (CALR), a key driver in MPN pathogenesis.

The data presented at ASH 2025 illustrate how the Tapestri’s single-cell data was leveraged to understand disease persistence and clonal expansion in MPNs. Subsequently, Tapestri’s single-cell DNA and protein profiling was applied to gain deeper insights into clonal evolution, disease progression, and treatment response in patients with MPNs.

Click the button below to read the entire Press Release:

Continue Reading The Press Release